ITGAM and graft versus host disease: Furthermore, the GVHD-inhibiting capacity of CD11b+CD11c+ MDSC requires confirmation in other BMT models with disparities also in only MHC class II genes or disparities in MHC class I and II genes to exclude that the observed effects are model dependent.